Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants Blann AD; Khoo CWVasc Health Risk Manag 2009[]; 5 (ä): 693-704As the risk factors for thrombosis are becoming better understood, so is the need for anticoagulation. The inherent difficulties with warfarin are such that a low-molecular-weight heparin (LMWH) is often the key therapeutic. However, there are several different species of LMWH available to the practitioner, which leads to the need for an objective guide. New agents are coming onto the marketplace, and these may supersede both warfarin and the heparins. The current report will review the biochemistry and pharmacology of different LWMHs and identify which are more suitable for the different presentations of venous thromboembolism. It will conclude with a brief synopsis of new agents which may supersede warfarin and heparin.|Administration, Oral[MESH]|Anticoagulants/administration & dosage/adverse effects/*therapeutic use[MESH]|Female[MESH]|Hemorrhage/chemically induced[MESH]|Heparin, Low-Molecular-Weight/administration & dosage/adverse effects/*therapeutic use[MESH]|Humans[MESH]|Male[MESH]|Middle Aged[MESH]|Patient Selection[MESH]|Practice Guidelines as Topic[MESH]|Risk Assessment[MESH]|Risk Factors[MESH]|Treatment Outcome[MESH]|Venous Thromboembolism/*drug therapy/etiology/*prevention & control[MESH] |